Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 88

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Gain-of-function mutant p53: history and speculation

Bargonetti, Jill, Prives, Carol·2019·Journal of Molecular Cell Biology
DOI 10.1093/jmcb/mjz067
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jmcb/mjz067

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 51

  1. Aschauer, 2016, Novel targets and interaction partners of mutant p53 gain-of-function, Biochem. Soc. Trans., 44, 460, 10.1042/BST20150261 · DOI
  2. Baker, 1989, Chromosome 17 deletions and p53 gene mutations in colorectal carcinoma, Science, 244, 217, 10.1126/science.2649981 · DOI · Paper page
  3. Bargonetti, 1991, Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication, Cell, 65, 1083, 10.1016/0092-8674(91)90560-L · DOI · Paper page
  4. Bayle, 1995, The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity, Proc. Natl Acad. Sci. USA, 92, 5729, 10.1073/pnas.92.12.5729 · DOI
  5. Bellazzo, 2018, Complexes formed by mutant p53 and their roles in breast cancer, Breast Cancer, 10, 101
  6. Dittmer, 1993, Gain of function mutations in p53, Nature Genet., 4, 42, 10.1038/ng0593-42 · DOI · Paper page
  7. Eliyahu, 1989, Wild-type p53 can inhibit oncogene-mediated focus formation, Proc. Natl Acad. Sci. USA, 86, 8763, 10.1073/pnas.86.22.8763 · DOI · Paper page
  8. Finlay, 1988, Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life, Mol. Cell. Biol., 8, 531, 10.1128/MCB.8.2.531 · DOI · Paper page
  9. Fischbach, 2018, The C-terminal domain of p53 orchestrates the interplay between non-covalent and covalent poly(ADP-ribosyl)ation of p53 by PARP1, Nucleic Acids Res., 46, 804, 10.1093/nar/gkx1205 · DOI
  10. Fischer, 2016, p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis, Cell Cycle, 15, 3210, 10.1080/15384101.2016.1241917 · DOI
  11. Fischer, 2018, Association between the oligomeric status of p53 and clinical outcomes in Li–Fraumeni syndrome, J. Natl Cancer Inst., 110, 1418, 10.1093/jnci/djy114 · DOI
  12. Freed-Pastor, 2012, Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway, Cell, 148, 244, 10.1016/j.cell.2011.12.017 · DOI · Paper page
  13. Freed-Pastor, 2012, Mutant p53: one name, many proteins, Genes Dev., 26, 1268, 10.1101/gad.190678.112 · DOI · Paper page
  14. Gottifredi, 2018, The tip of an iceberg: replication-associated functions of the tumor suppressor p53, Cancers, 10, pii: E250, 10.3390/cancers10080250 · DOI
  15. Hanzlikova, 2018, The importance of poly(ADP-ribose) polymerase as a sensor of unligated Okazaki fragments during DNA replication, Mol. Cell, 71, 319, 10.1016/j.molcel.2018.06.004 · DOI · Paper page
  16. Hinds, 1989, Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation, J. Virol., 63, 739, 10.1128/JVI.63.2.739-746.1989 · DOI · Paper page
  17. Hinds, 1990, Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the `hot spot' mutant phenotypes, Cell Growth Differ., 1, 571
  18. Kern, 1991, Mutant p53 proteins bind DNA abnormally in vitro, Oncogene, 6, 131
  19. Kim, 2018, Mutant p53 partners in crime, Cell Death Differ., 25, 161, 10.1038/cdd.2017.185 · DOI · Paper page
  20. Klusmann, 2016, p53 activity results in DNA replication fork processivity, Cell Rep., 17, 1845, 10.1016/j.celrep.2016.10.036 · DOI
  21. Lane, 2019, p53: updates on mechanisms, biology and therapy (I), J. Mol. Cell Biol., 11, 185, 10.1093/jmcb/mjz017 · DOI
  22. Laptenko, 2015, The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain, Mol. Cell, 57, 1034, 10.1016/j.molcel.2015.02.015 · DOI · Paper page
  23. Laptenko, 2016, The tail that wags the dog: how the disordered C-terminal domain controls the transcriptional activities of the p53 tumor-suppressor protein, Trends Biochem. Sci., 41, 1022, 10.1016/j.tibs.2016.08.011 · DOI · Paper page
  24. Lee, 1995, p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches, Cell, 81, 1013, 10.1016/S0092-8674(05)80006-6 · DOI · Paper page
  25. Li, 2007, Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?, Oncogene, 26, 2220, 10.1038/sj.onc.1210311 · DOI · Paper page
  26. Lin, 1994, Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein, Genes Dev., 8, 1235, 10.1101/gad.8.10.1235 · DOI · Paper page
  27. Linzer, 1979, Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells, Cell, 17, 43, 10.1016/0092-8674(79)90293-9 · DOI · Paper page
  28. Liu, 2017, Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin, Proc. Natl Acad. Sci. USA, 114, E3766, 10.1073/pnas.1619832114 · DOI
  29. Lu, 2017, p53 and MDM2: their Yin-Yang intimacy, J. Mol. Cell Biol., 9, 1, 10.1093/jmcb/mjx003 · DOI
  30. Mantovani, 2019, Mutant p53 as a guardian of the cancer cell, Cell Death Differ., 26, 199, 10.1038/s41418-018-0246-9 · DOI · Paper page
  31. Miller, 1995, p53 inhibits DNA replication in vitro in a DNA-binding-dependent manner, Mol. Cell. Biol., 15, 6554, 10.1128/MCB.15.12.6554 · DOI
  32. Morselli, 2008, Mutant p53 protein localized in the cytoplasm inhibits autophagy, Cell Cycle, 7, 3056, 10.4161/cc.7.19.6751 · DOI · Paper page
  33. Muller, 2013, p53 mutations in cancer, Nat. Cell Biol., 15, 2, 10.1038/ncb2641 · DOI · Paper page
  34. Nigro, 1989, Mutations in the p53 gene occur in diverse human tumor types, Nature, 342, 705, 10.1038/342705a0 · DOI · Paper page
  35. Notterman, 1998, Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity, Oncogene, 17, 2743, 10.1038/sj.onc.1202210 · DOI
  36. Oren, 1983, Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen, Proc. Natl Acad. Sci. USA, 80, 56, 10.1073/pnas.80.1.56 · DOI
  37. Pfister, 2015, Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells, Genes Dev., 29, 1298, 10.1101/gad.263202.115 · DOI
  38. Pfister, 2016, Chromatin dysregulation by mutant p53, Oncotarget, 7, 29875, 10.18632/oncotarget.7922 · DOI
  39. Pfister, 2017, Transcriptional regulation by wild-type and cancer-related mutant forms of p53, Cold Spring Harb. Perspect. Med., 7, pii: a026054, 10.1101/cshperspect.a026054 · DOI
  40. Polotskaia, 2015, Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4, Proc. Natl Acad. Sci. USA, 112, E1220, 10.1073/pnas.1416318112 · DOI
  41. Pourebrahim, 2017, Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein, Genes Dev., 31, 1847, 10.1101/gad.304972.117 · DOI
  42. Qiu, 2017, Identification, validation, and targeting of the mutant p53–PARP–MCM chromatin axis in triple negative breast cancer, NPJ Breast Cancer, 3, pii: 1, 10.1038/s41523-016-0001-7 · DOI
  43. Raj, 2017, The transactivation domains of the p53 protein, Cold Spring Harb. Perspect. Med., 7, pii: a026047, 10.1101/cshperspect.a026047 · DOI · Paper page
  44. Roy, 2018, p53 orchestrates DNA replication restart homeostasis by suppressing mutagenic RAD52 and POLθ pathways, eLife, 7, pii: e31723, 10.7554/eLife.31723 · DOI
  45. Scian, 2004, Modulation of gene expression by tumor-derived p53 mutants, Cancer Res., 64, 7447, 10.1158/0008-5472.CAN-04-1568 · DOI
  46. Shetzer, 2016, Oncogenic mutant p53 gain of function nourishes the vicious cycle of tumor development and cancer stem-cell formation, Cold Spring Harb. Perspect. Med., 6, pii: a026203, 10.1101/cshperspect.a026203 · DOI
  47. Shtraizent, 2016, Hot spot mutation in TP53 (R248Q) causes oncogenic gain-of-function phenotypes in a breast cancer cell line derived from an African American patient, Int. J. Environ. Res. Public Health, 13, ijerph13010022
  48. Vogelstein, 2013, Cancer genome landscapes, Science, 339, 1546, 10.1126/science.1235122 · DOI · Paper page
  49. Yan, 2010, Characterization of functional domains necessary for mutant p53 gain of function, J. Biol. Chem., 285, 14229, 10.1074/jbc.M109.097253 · DOI
  50. Zhu, 2015, Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth, Nature, 525, 206, 10.1038/nature15251 · DOI · Paper page
  51. Zhu, 2000, Definition of the p53 functional domains necessary for inducing apoptosis, J. Biol. Chem., 275, 39927, 10.1074/jbc.M005676200 · DOI

Cited by

See all 88

Metadata

Authors
Bargonetti, J., & Prives, C.
Affiliations
  • Department of Biological Sciences Hunter College and The Graduate Center, City University of New York, New York, NY 10021, USA
  • Department of Biological Sciences, Columbia University, New York, NY 10027, USA
Venue
Journal of Molecular Cell Biology
Publisher
Oxford University Press (OUP)
Published
2019-07
Volume
11
Issue
7
Pages
605-609
ISSN
1759-4685
DOI
10.1093/jmcb/mjz067
Cited by
88
References
4
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor, 7 d)
Funders
  • Breast Cancer Research Foundation (BCRF-18-011)
  • National Institutes of Health-National Cancer Institute (CA87497)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gain-of-function mutant p53: history and speculation. https://app.cochat.ai/papers/10.1093/jmcb/mjz067
The paper
Bargonetti, J., & Prives, C. (2019). Gain-of-function mutant p53: history and speculation. Journal of Molecular Cell Biology. https://doi.org/10.1093/jmcb/mjz067

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.